Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD)
considering the disease as a continuum. Thanks to evolving biomarker research and …

Background Blood-based biomarkers for Alzheimer's disease (AD) might facilitate
identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation …

Although amyloid imaging with PiB-PET ([C-11] Pittsburgh Compound-B positron emission
tomography), and now with F-18-labeled tracers, has produced remarkably consistent …

TREM 2 is an innate immune receptor expressed on the surface of microglia. Loss‐of‐
function mutations of TREM 2 are associated with increased risk of Alzheimer's disease …

A deeper understanding of the molecular processes underlying late-onset Alzheimer's
disease (LOAD) could aid in biomarker and drug target discovery. Using high-throughput …

Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in
2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …